Payment overview · 2025
General Payments
$418.72
30 reported records · 11 companies
Healthcare provider profile · identity verified
Melissa K Rosso, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MANHATTAN, KS · NPI 1720216708
Verified facts
What the public records show
CMS Open Payments records show Melissa K Rosso, MD received $418.72 in general payments during 2025 across 30 reported records.
PFIZER INC. accounted for 38.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $162.01 | 38.7% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.06 | 23.2% | 5 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.41 | 6.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $22.82 | 5.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.00 | 4.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.43 | 3.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.37 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.92 | 3.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.07 | 3.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.63 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.00 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $418.72 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.62 | 14 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $107.79 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.80 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.39 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $22.82 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $9.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 17 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 251 | 50 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 52 |
| Losartan Potassium | Losartan Potassium | 182 | 39 |
| Sertraline Hcl | Sertraline Hcl | 143 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 130 | 32 |
| Omeprazole | Omeprazole | 125 | 34 |
| Lisinopril | Lisinopril | 113 | 29 |
| Donepezil Hcl | Donepezil Hcl | 100 | 13 |
| Furosemide | Furosemide | 96 | 18 |
| Famotidine | Famotidine | 91 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 84 | 24 |
| Ozempic | Semaglutide | 82 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 20 |
| Meloxicam | Meloxicam | 72 | 24 |
| Farxiga | Dapagliflozin Propanediol | 70 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 12 |
| Gabapentin | Gabapentin | 62 | 16 |
| Tramadol Hcl | Tramadol Hcl | 61 | 14 |
| Eliquis | Apixaban | 60 | 12 |
| Potassium Chloride | Potassium Chloride | 57 | 11 |
| Spironolactone | Spironolactone | 54 | suppressed |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 17 |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Prednisone | Prednisone | 46 | 16 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Baclofen | Baclofen | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Matzim La | Diltiazem Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $418.72 · 30 records | PFIZER INC. | ABRYSVO, BEYFORTUS, CAPLYTA, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, NURTEC ODT, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error